thumbnail

Most Prescribed Medications in the USA

List the top 10 most prescribed and the top 10 most costly medications for Medicare Part D patients in the United States.
source: data.cms.gov
as of 2021 data
Quiz by
herosinger
Rate:
Last updated: February 15, 2024
You have not attempted this quiz yet.
First submittedOctober 4, 2017
Times taken246
Average score25.0%
Report this quizReport
5:00
Enter answer here
0
 / 20 guessed
The quiz is paused. You have remaining.
Scoring
You scored / = %
This beats or equals % of test takers also scored 100%
The average score is
Your high score is
Your fastest time is
Keep scrolling down for answers and more stats ...
Medicare Claims
Total Spending
Drug
Drug Class
Average Cost / Patient
61.1M
$836M
Atorvastatin
Cardiovascular
$56 / yr
44.2M
$310M
Amlodipine
Cardiovascular
$30 / yr
38.4M
$728M
Levothyroxine
Endocrine
$91 / yr
36.1M
$260M
Lisinopril
Cardiovascular
$30 / yr
33.0M
$622M
Gabapentin
Neurology
$90 / yr
29.4M
$393M
Losartan
Cardiovascular
$55 / yr
28.3M
$439M
Omeprazole
Gastrointestinal
$62 / yr
26.2M
$587M
Metoprolol
Cardiovascular
$95 / yr
24.2M
$182M
Metformin
Endocrine
$31 / yr
23.4M
$140M
Furosemide
Cardiovascular
$25 / yr
Medicare Claims
Total Spending
Drug
Drug Class
Average Cost / Patient
17.1M
$12.58B
Eliquis
Cardiovascular
$4,024 / yr
344K
$5.89B
Revlimid
Cancer
$129,242 / yr
6.4M
$5.23B
Xarelto
Cardiovascular
$4,154 / yr
3.7M
$4.70B
Trulicity
Endocrine
$7,084 / yr
4.5M
$4.06B
Januvia
Endocrine
$4,344 / yr
3.8M
$3.74B
Jardiance
Cardiovascular
$4,224 / yr
231K
$3.15B
Imbruvica
Cancer
$120,958 / yr
375K
$2.91B
Humira Pen
Antirheumatic
$56,752 / yr
4.6M
$2.83B
Lantus Solostar
Endocrine
$2,685 / yr
2.0M
$2.62B
Ozempic
Endocrine
$5,717 / yr
Save Your Stats
Your Next Quiz
Name all 50 states in the USA. Easy, right?
Can you name the ten Asian countries with the largest GDPs?
20 random countries have been removed from the map of the world! Can you identify them in 3 minutes?
Drag the flag onto the correct country. Careful, though! One wrong move and the game ends.
Comments
No comments yet